Employees Retirement System of Texas Purchases 6,560 Shares of Novo Nordisk A/S (NYSE:NVO)

Employees Retirement System of Texas lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,964 shares of the company's stock after purchasing an additional 6,560 shares during the period. Employees Retirement System of Texas' holdings in Novo Nordisk A/S were worth $6,276,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Brucke Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $542,000. Carolinas Wealth Consulting LLC increased its holdings in Novo Nordisk A/S by 920.6% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 1,092 shares of the company's stock valued at $94,000 after buying an additional 985 shares in the last quarter. LM Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $208,000. Armis Advisers LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $241,000. Finally, Polar Asset Management Partners Inc. boosted its position in Novo Nordisk A/S by 86.0% during the fourth quarter. Polar Asset Management Partners Inc. now owns 27,900 shares of the company's stock worth $2,400,000 after acquiring an additional 12,900 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO traded up $0.26 during mid-day trading on Thursday, reaching $68.86. The company had a trading volume of 5,889,766 shares, compared to its average volume of 9,407,681. The company's 50 day simple moving average is $65.74 and its 200 day simple moving average is $82.29. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a market capitalization of $309.02 billion, a price-to-earnings ratio of 20.93, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.